


Journal Pre-proof

Dupilumab Efficacy in Patients with Uncontrolled or Oral Corticosteroid-Dependent Allergic and Non-allergic Asthma

Guy Brusselle, MD, Santiago Quirce, MD, Alberto Papi, MD, Piotr Kuna, MD, Bradley E. Chipps, MD, Nicola A. Hanania, MD, Michael Blaiss, MD, Jérôme Msihid, MS, Juby A. Jacob-Nara, MD, Yamo Deniz, MD, Paul J. Rowe, MD, Rebecca Gall, MD, Benjamin Ortiz, MD, Michel Djandji, MD, Amr Radwan, MBBChir



PII: S2213-2198(22)01311-3

DOI: <https://doi.org/10.1016/j.jaip.2022.11.044>

Reference: JAIP 4555

To appear in: *The Journal of Allergy and Clinical Immunology: In Practice*

Received Date: 11 October 2021

Revised Date: 21 November 2022

Accepted Date: 29 November 2022

Please cite this article as: Brusselle G, Quirce S, Papi A, Kuna P, Chipps BE, Hanania NA, Blaiss M, Msihid J, Jacob-Nara JA, Deniz Y, Rowe PJ, Gall R, Ortiz B, Djandji M, Radwan A, Dupilumab Efficacy in Patients with Uncontrolled or Oral Corticosteroid-Dependent Allergic and Non-allergic Asthma, *The Journal of Allergy and Clinical Immunology: In Practice* (2023), doi: <https://doi.org/10.1016/j.jaip.2022.11.044>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology

Dupilumab Efficacy in Patients with Uncontrolled or Oral Corticosteroid-Dependent Allergic and Non-allergic Asthma

Guy Brusselle, MD^a, Santiago Quirce, MD^b, Alberto Papi, MD^c, Piotr Kuna, MD^d, Bradley E. Chipps, MD^e, Nicola A. Hanania, MD^f, Michael Blaiss, MD^g, Jérôme Msihid, MS^h, Juby A. Jacob-Nara, MDⁱ, Yamo Deniz, MDⁱ, Paul J. Rowe, MDⁱ, Rebecca Gall, MDⁱ, Benjamin Ortiz, MDⁱ, Michel Djandji, MD^k, and Amr Radwan, MBBChir^j
Ghent, Belgium; Madrid, Spain; Ferrara, Italy; Łódź, Poland; Sacramento, CA, USA; Houston, TX, USA; Augusta, GA, USA; Chilly-Mazarin, France; Bridgewater, NJ, USA; Tarrytown, NY, USA; Cambridge, MA, USA

Affiliations

^aGhent University Hospital, Ghent, Belgium

^bHospital Universitario La Paz, IdiPAZ, CIBERES, Madrid, Spain

^cRespiratory Medicine Unit, University of Ferrara, S. Anna University Hospital, Ferrara, Italy

^dMedical University of Łódź, Łódź, Poland

^eCapital Allergy and Respiratory Disease Center, Sacramento, CA, USA

^fSection of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA

^gMedical College of Georgia at Augusta University, Augusta, GA, USA

^hSanofi, Chilly-Mazarin, France

ⁱSanofi, Bridgewater, NJ, USA

^jRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

^kSanofi, Cambridge, MA, USA

Corresponding author: Guy Brusselle, MD

Address: Ghent University Hospital, Ghent, Belgium

C. Heymanslaan 10, ingang 12 - verdieping 6

9000 Gent

Phone: +3293322604

Email: guy.brusselle@ugent.be

Target journal: *JACI in Practice*

Title: 11/12

Word count: 3488/3500

Abstract: 249/250

Tables/figures: 2/6

Funding: Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.

ClinicalTrials.gov Identifiers: P2B: NCT01854047; VENTURE: NCT02528214.

Conflict of interest: G. Brusselle reports consultancy and speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, Sanofi, and Teva. S. Quirce reports organization of educational events, advisory board membership, and speaker honoraria from ALK, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, Regeneron Pharmaceuticals, Inc., Sanofi, and Teva. A. Papi reports grants, personal fees, non-financial support, and other from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Mundipharma, and Teva; has received personal fees and non-financial support from Menarini, Novartis, and Zambon; and has received grants from Sanofi. P. Kuna has no conflicts of interest to disclose. B.E. Chipps reports consultancy and speaker fees from AstraZeneca, Boehringer Ingelheim, Circassia, Genentech, Novartis, Regeneron Pharmaceuticals, Inc., Sanofi, and Teva. N.A. Hanania reports research support from AstraZeneca, Boehringer Ingelheim, and GSK; is a consultant for AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Regeneron

57 Pharmaceuticals, Inc., and Sanofi. M. Blais has no conflicts of interest to disclose. J.
58 Msihid, J.A. Jacob-Nara, P.J. Rowe, and M. Djandji are Sanofi employees and may hold
59 stock and/or stock options in the company. Y. Deniz, R. Gall, B. Ortiz, and A. Radwan are
60 employees and shareholders of Regeneron Pharmaceuticals, Inc.

61

ABSTRACT

BACKGROUND: Type 2 cytokines interleukin (IL)-4/IL-5/IL-13 play an important role in pathogenesis of type 2 conditions, including asthma. Dupilumab, a human monoclonal antibody, blocks the shared receptor component for IL-4/IL-13, inhibiting signaling. In phase 2b (P2B) (NCT01854047) and phase 3 VENTURE (NCT02528214), dupilumab reduced annualized severe exacerbations rates (AER), improved forced expiratory volume in one second (FEV₁), and was generally well tolerated in patients with uncontrolled, moderate-to-severe or oral-corticosteroid (OCS)-dependent severe asthma.

OBJECTIVE: Post-hoc assessment of dupilumab efficacy vs placebo in P2B and VENTURE in patients stratified by allergic status.

METHODS: Allergic asthma was defined as total serum immunoglobulin E (IgE) ≥ 30 IU/mL and ≥ 1 perennial aeroallergen-specific IgE ≥ 0.35 kU/L at baseline. AER, pre-bronchodilator (BD) FEV₁, FEV₁/forced vital capacity (FVC) ratio, asthma control (5-item Asthma Control Questionnaire [ACQ-5]), health-related quality of life (HRQoL; Asthma Quality of Life Questionnaire [AQLQ]), type 2 biomarkers, specific IgE, and OCS reduction (VENTURE only) were assessed.

RESULTS: In patients with allergic asthma, dupilumab (P2B: pooled 200/300mg; VENTURE: 300mg) every 2 weeks vs placebo reduced AER (P2B: -60%, $P < .01$; VENTURE: -72%, $P < .001$), and, in P2B, increased pre-BD FEV₁ ($P < .01$) and FEV₁/FVC ($P < .05$). In both studies, dupilumab significantly improved asthma control and HRQoL and reduced most type 2 biomarkers. Dupilumab significantly reduced OCS use in VENTURE. Similar benefits were observed in patients without evidence of allergic asthma.

CONCLUSIONS: Dupilumab significantly reduced AER and improved lung function and asthma control and HRQoL in patients with or without evidence of allergic asthma.

Clinical trial registration number: P2B: NCT01854047; VENTURE: NCT02528214

Highlights Box***What is already known about this topic?*** [35 words]

Interleukin 4/13 play a key role in airway inflammation. Dupilumab can suppress type 2 inflammatory biomarkers in patients with uncontrolled, moderate-to-severe asthma with or without evidence of allergic asthma, one of the most common forms of asthma.

What does this article add to our knowledge? [33 words]

In this analysis of patients with uncontrolled, moderate-to-severe or oral corticosteroid-dependent severe asthma, dupilumab reduced severe exacerbation rates and improved lung function, asthma control, and quality-of-life in patients with or without evidence of allergic asthma.

How does this study impact current management guidelines? [33 words]

The results of this study indicate that dupilumab is beneficial in reducing the clinical burden of disease in patients with uncontrolled moderate-to-severe or corticosteroid-dependent, severe asthma with and without evidence of allergic asthma.

Key words

Dupilumab; Allergic asthma; Exacerbation; IL-4, IL-13, IgE; Biomarkers; ACQ-5; AQLQ; FEV₁

108 *Abbreviations used*109 *ACQ-5- Asthma Control Questionnaire*110 *AER- Annualized severe exacerbations rate*111 *ANCOVA- Analysis of covariance*112 *AQLQ- Asthma Quality of Life Questionnaire*113 *BD- Bronchodilator*114 *BL- Baseline*115 *BMI- Body Mass Index*116 *CI- Confidence interval*117 *FeNO- Fractional exhaled nitric oxide*118 *FEV₁- Forced expiratory volume in one second*119 *FVC- Forced vital capacity*120 *GINA- Global Initiative for Asthma*121 *HRQoL- Health-related quality of life*122 *ICS- Inhaled corticosteroid*123 *Ig- Immunoglobulin*124 *IL- Interleukin*125 *ITT- Intent-to-treat*126 *LS- Least squares*127 *LSMD- Least squares mean difference*128 *OCS- Oral corticosteroid*129 *P2B- Phase 2b*130 *Q- Quartile*131 *q2w- Every 2 weeks*132 *q4w- Every 4 weeks*133 *QoL- quality of life*134 *SD- Standard deviation*135 *SE- Standard error*

- 136 *SGRQ- St Georges Respiratory Questionnaire*
- 137 *STAT6- Signal transducer and activator of transcription 6*
- 138 *TARC- Thymus and activation-regulated chemokine*
- 139 *TEAE- Treatment-emergent adverse event*
- 140 *Th- T helper*
- 141

INTRODUCTION

Allergic asthma is characterized by increased levels of total and allergen-specific immunoglobulin E (IgE) in serum.¹ Type 2 inflammatory cytokines, particularly interleukin (IL)-4, IL-5, and IL-13, play key roles in the pathogenesis of multiple type 2 inflammatory conditions, including atopic dermatitis, chronic rhinosinusitis with nasal polyps, and allergic asthma. One of the many roles of IL-4 in type 2 inflammatory responses is in differentiation of naive T helper (Th) cells into Th2 cells, which then produce type 2 inflammatory cytokines and chemokines.² Additionally, IL-4 induces B-cell class switching from production of IgG to IgE.³ IL-5 stimulates eosinopoiesis and activates eosinophils, and IL-13 plays a key role in goblet cell hyperplasia, mucus hypersecretion, airway hyperresponsiveness, and eosinophil migration into the lung.^{4,5}

Biomarkers modulated by IL-4 and IL-13 have been linked to type 2 inflammatory processes in patients with asthma, including thymus and activation-regulated chemokine (TARC), fractional exhaled nitric oxide (FeNO), and serum total and allergen-specific IgE levels. TARC plays a role in the recruitment of Th2 cells in allergic diseases such as allergic asthma. IL-4 induces expression of TARC as part of the signal transducer and activator of transcription 6 (STAT6) signaling pathway;⁶ and elevated levels of TARC have been observed in both serum and sputum of patients with asthma.⁷ Nitric oxide acts as an important inflammatory mediator in the respiratory tract and is regulated in part by IL-13.⁸ IgE has multiple effects in the pathogenesis of allergic processes, including activation and degranulation of mast cells, basophils, and eosinophils, leading to release of pro-inflammatory mediators, recruitment of eosinophils, and bronchoconstriction.^{9,10} Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for IL-4 and IL-13, thus inhibiting their signaling.^{11,12} It is indicated for use in patients with type 2 inflammatory diseases, including atopic dermatitis, asthma (regardless of allergic status), and chronic rhinosinusitis with nasal polyps.^{13,14} In the phase 2b dose-ranging study (P2B; NCT01854047), add-on dupilumab 200/300 mg every 2 weeks (q2w) vs placebo reduced annualized rates of severe exacerbations and improved lung function, and was generally

170 well tolerated, in patients with uncontrolled, moderate-to-severe asthma.¹⁵ Additionally, in the
171 phase 3 LIBERTY ASTHMA VENTURE study (NCT02528214), add-on dupilumab 300 mg
172 therapy significantly reduced oral corticosteroid (OCS) use while simultaneously reducing
173 the rate of severe asthma exacerbations and improving lung function in patients with OCS-
174 dependent, severe asthma.¹⁶

175 In a previous post-hoc analysis of the phase 3 LIBERTY ASTHMA QUEST study,
176 dupilumab significantly reduced the rate of severe exacerbations, and improved FEV₁, and
177 asthma control, in moderate-to-severe asthma patients with or without evidence of allergic
178 asthma.¹⁷

179 This post-hoc analysis aims to confirm outcomes observed in QUEST¹⁷ in patients
180 with and without evidence of allergic asthma with uncontrolled, moderate-to-severe asthma
181 from the P2B study and with OCS-dependent, severe asthma from the VENTURE study.

182

METHODS

Study design

Full details of the P2B and VENTURE study design have been published previously.^{15,16} In brief, the P2B dose-ranging study was a phase 2b randomized, double-blind, placebo-controlled, parallel group study performed in adult patients with uncontrolled moderate-to-severe asthma despite use of medium-to-high dose inhaled corticosteroids (ICS). Patients were randomized 1:1:1:1:1 to receive subcutaneous dupilumab 200 mg (n = 150) or 300 mg (n = 157) every 2 weeks (q2w) or 200 mg (n = 154) or 300 mg (n = 157) every 4 weeks (q4w), or placebo (n = 158) for a 24-week treatment period. This post-hoc analysis included the combined dupilumab 200 mg and 300 mg q2w population (n = 307). VENTURE was a phase 3 randomized, double-blind, placebo-controlled study in adolescents and adults with OCS-dependent severe asthma. Patients were randomized 1:1 to receive dupilumab 300 mg q2w (n = 103) or placebo (n = 107) for 24 weeks. The OCS dose was adjusted every 4 weeks from week 4 to week 20 according to a protocol-prespecified algorithm. Both studies were conducted in accordance with the Declaration of Helsinki, International Conference on Harmonisation Good Clinical Practice guidelines and applicable regulatory requirements. All patients or their legal guardians/parents provided written informed consent before participating in the studies. Protocol and consent forms were approved by local institutional review boards and ethics committees prior to commencement of the studies.

Patients

P2B enrolled adult patients with a diagnosis of asthma for ≥ 12 months based on Global Initiative for Asthma (GINA) 2009 guidelines;¹⁸ existing treatment with medium-to-high-dose ICS plus a long-acting β_2 agonist; pre-bronchodilator (BD) FEV₁ of 40-80% predicted at baseline; ACQ-5 score ≥ 1.5 at screening and baseline; and FEV₁ reversibility of $\geq 12\%$ and ≥ 200 mL after 200-400 μ g salbutamol at screening. VENTURE enrolled adolescent and adult patients with physician-diagnosed asthma for ≥ 12 months based on

GINA 2014 guidelines:¹⁹ regular OCS treatment in the previous 6 months (5-35 mg prednisone or equivalent), high-dose ICS in combination with up to two controllers for ≥ 3 months, pre-BD FEV₁ $\leq 80\%$ predicted ($\leq 90\%$ for adolescents), and reversibility $\geq 12\%$ and 200 mL in FEV₁. Further details of inclusion and exclusion criteria have been published previously.^{15,16}

No prick test was used in either study. For this post-hoc analysis, patients were categorized as meeting or not meeting the criteria for allergic asthma as used by physicians to determine eligibility for biologic therapy with omalizumab: total serum IgE ≥ 30 IU/mL and at least one perennial aeroallergen-specific IgE ≥ 0.35 kU/L at baseline.²⁰ Perennial allergens analyzed in both studies were *Alternaria tenuis/alternata*, *Cladosporium herbarum/hormodendrum*, *Aspergillus fumigatus*, cat and dog dander, *Dermatophagoides farinae*, *Dermatophagoides pteronyssinus*, oriental cockroach, and, for P2B only, German cockroach.

Endpoints

Endpoints assessed for both studies were: annualized severe exacerbation rates (defined as events leading to hospitalization or an emergency department visit requiring systemics corticosteroids [SCS] or treatment for ≥ 3 days SCS[at ≥ 2 times the current dose of oral glucocorticoid for patients in VENTURE]), change from baseline in pre-BD FEV₁, FEV₁/FVC ratio, 5-item Asthma Control Questionnaire (ACQ-5) score, Asthma Quality of Life Questionnaire (AQLQ) global score, type 2 biomarkers (total IgE, FeNO, and serum TARC), and specific IgE for each of the perennial allergens over the 24-week treatment periods. Percentage reduction in OCS use was also assessed for patients in VENTURE.

Statistical analysis

Data were analyzed for subgroups of patients with allergic asthma vs those not meeting criteria for allergic asthma for each study separately, in the intent-to-treat (ITT)

population for efficacy parameters and in the exposed population for biomarkers. In P2B, data were combined across dupilumab q2w doses.

Annualized severe exacerbation rates over the 24-week study periods were analyzed using a negative binomial regression model; total number of events onset between first dose date and last dose date + 14 days for P2B and between first dose date and week 24 or last contact date (whichever came earlier) for VENTURE were the response variables, with treatment group, pooled countries/regions, number of severe exacerbation events prior to study, and baseline eosinophil strata (plus baseline optimized OCS dose for VENTURE) as covariates, and log-transformed standardized treatment duration as an offset variable, for both studies.

Change from baseline in pre-BD FEV₁ and FEV₁/FVC ratios, ACQ-5 score, and AQLQ global score were assessed in each subgroup using mixed-effect models with repeated measures. Treatment group, pooled countries/regions, baseline eosinophil strata, visits, baseline optimized OCS dose (for VENTURE), treatment by-visit interaction, baseline values, and baseline-by-visit interaction were covariates; age, gender, and height were added as covariates for pre-BD FEV₁ and FEV₁/FVC ratio in VENTURE.

For VENTURE, absolute and percentage reductions of OCS dose at week 24 were analyzed in each subgroup using an analysis of covariance (ANCOVA) model; treatment group, baseline optimized OCS dose, pooled countries/regions, and baseline eosinophil strata were covariates. For patients who discontinued or had missing data on oral glucocorticoid dose at week 24, missing data were handled with the use of a pattern-mixture model by multiple imputations.

For VENTURE, the proportion of patients with ≥50% reduction in OCS dose – achieving reduction of OCS dose to <5 mg/day, achieving maximum possible reduction of OCS dose per protocol, and no longer requiring OCS at week 24 (for patients with baseline OCS dose ≤30 mg/day) – were compared in each subgroup using a logistic regression model; treatment group, optimized OCS dose at baseline, pooled countries/regions, and

baseline eosinophil level subgroup were covariates. Missing data were imputed the same way as for percentage reduction of OCS dose.

Change from baseline in type 2 biomarkers and specific IgE were assessed in the exposed population, and separately in each subgroup, using rank ANCOVA models due to non-normal distribution of the endpoints; baseline biomarker level, pooled countries/regions, baseline eosinophil strata, and baseline optimized OCS dose for VENTURE were covariates. Similar analyses were performed in patients with evidence of allergic asthma for percent change from baseline in IgE-specific allergens (only patients with positive specific allergens at baseline were included in the analyses).

Across all analyses, significance was attributed as $P < .05$. As all predictive analyses were post hoc, all P values were not adjusted for multiple testing and should be considered nominal. Analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, NC).

RESULTS

Patients

In total, 271 patients with (placebo $n = 95$; dupilumab $n = 176$; 58.3% of the ITT population) and 194 patients without evidence of allergic asthma (placebo $n = 63$; dupilumab $n = 131$) from P2B, and 86 patients with (placebo $n = 40$; dupilumab $n = 46$; 41.0% ITT) and 124 patients without evidence of allergic asthma (placebo $n = 67$; dupilumab $n = 57$) from VENTURE were included in the analysis. Of the patients without evidence of allergic asthma in P2B, 48 vs 96 patients had baseline total IgE ≥ 30 IU/mL but no positive perennial allergen, 6 vs 8 had total IgE < 30 IU/mL but ≥ 1 positive perennial allergen, and 9 vs 27 had total IgE < 30 IU/mL and no positive perennial allergens for the placebo and dupilumab groups, respectively. In VENTURE these numbers of patients were 48 vs 47, 2 vs 0, and 17 vs 10 for the two treatment groups, respectively.

Patients with allergic asthma tended to be younger and had earlier age of asthma onset than patients without evidence of allergic asthma (Table I). Rates of atopic medical conditions were also higher in patients with allergic asthma. No clear differences in baseline type 2 biomarkers (except for total and allergen-specific IgE) were observed between groups of patients stratified by allergic status (Table E1 in this article's Online Repository at www.jaci-inpractice.org).

Annualized severe exacerbation rate

In both studies, significantly lower rates of severe exacerbations were seen in the dupilumab vs placebo groups, irrespective of allergic status (Figure 1). In patients with allergic asthma, 60% (risk ratio: 0.38; 95% confidence interval [CI]: 0.21, 0.77; $P = .0063$) reduction vs placebo was observed in P2B, and 72% (risk ratio: 0.28; 95% CI: 0.13, 0.58; $P = .0008$) in VENTURE; in patients without evidence of allergic asthma, these reductions were 86% (risk ratio: 0.14; 95% CI: 0.06, 0.34; $P < .0001$) and 45% (risk ratio: 0.55; 95% CI: 0.31, 0.96; $P = .0358$), respectively (Figure 1). While the most pronounced disease burden

(exacerbation rate) can be observed in patients with uncontrolled, moderate-to-severe asthma without evidence of allergic asthma (Figure 1, A), it is worth noting that exacerbation frequency in patients with OCS-dependent, severe asthma is high, irrespective of allergic status (Figure 1, B).

Effect of dupilumab on OCS use (VENTURE only)

Dupilumab vs placebo led to a greater reduction in OCS use from baseline to week 24 in both patients with (least squares [LS] mean [SE]: 73.1% [7.4] vs 40.6% [7.2]; $P = .0007$) and without (69.3% [6.7] vs 41.8% [6.1]; $P = .0015$) evidence of allergic asthma. When assessed over time, differences between treatment groups were evident from week 12 onwards for patients with or without evidence of allergic asthma. Significant absolute reductions from baseline in OCS use were observed in patients with allergic asthma (LS mean difference [LSMD] vs placebo [95% CI]: 3.87 mg/day [1.65, 6.09]; $P = .0006$), and in patients without evidence of allergic asthma (LSMD [95% CI]: 2.27 mg/day [0.26, 4.28]; $P = .0268$) (Figure 2). Overall, the proportion of patients achieving at least 50% OCS dose reductions, reductions to <5 mg/day, maximum possible reductions per protocol, and no longer requiring OCS at week 24 were similar in patients treated with dupilumab regardless of allergic status, with significantly greater reductions for dupilumab vs placebo in all outcomes ($P < .05$; Table E2 in this article's Online Repository at www.jaci-inpractice.org).

Lung function

In P2B, significantly greater improvements in pre-BD FEV₁ were observed for dupilumab vs placebo in patients with allergic asthma as early as week 2 (LSMD [95% CI]: 0.18 L [0.10, 0.26]; $P < .0001$); these were sustained until week 24 (LSMD [95% CI]: 0.15 L [0.06, 0.24]; $P = .0011$) (Figure 3, A). The difference between treatment groups in patients without evidence of allergic asthma was 0.16 L (0.04, 0.28) (LSMD [95% CI]; $P = .0104$) at week 24. In VENTURE, by end of treatment (week 24), dupilumab vs placebo improved pre-BD FEV₁ by 0.20 L (95% CI: -0.02, 0.43; $P = .0710$) in patients with allergic asthma. A

significantly greater improvement from baseline in dupilumab vs placebo was observed in patients without evidence of allergic asthma as early as week 2, and this was sustained to week 24 (LSMD [95% CI]: 0.22 L [0.07, 0.37]; $P = .0046$) (Table E3 in this article's Online Repository at www.jaci-inpractice.org).

The ratio of pre-BD FEV₁ to FVC is an important marker for airway obstruction. In P2B, significantly greater improvements in pre-BD FEV₁/FVC ratio were observed for dupilumab vs placebo in patients with allergic asthma as early as week 2; these were sustained over the treatment period (week 24; LSMD [95% CI]: 1.89 [0.36, 3.43%]; $P = .0159$) (Figure 3, B). Numerically greater improvements between treatment groups were observed in patients without evidence of allergic asthma at week 2; a significant difference was seen by end of treatment (week 24; LSMD [95% CI]: 2.66 [0.64, 4.67]; $P = .0101$). In VENTURE, although not significant, numerically greater differences in dupilumab vs placebo were observed in pre-BD FEV₁/FVC ratio between treatment groups in patients with OCS-dependent, severe asthma regardless of evidence of allergic asthma (Figure 3, B; see Table E4 in this article's Online Repository at www.jaci-inpractice.org).

Patient-reported outcomes

In P2B, significantly greater improvements from baseline in asthma control (ACQ-5 score) for dupilumab compared with placebo were seen from week 2 up to week 24 (LSMD [95% CI]: -0.35 [-0.60, -0.11]; $P = .0045$) in patients with allergic asthma; in patients without allergic asthma, numerically greater reductions were observed from week 2 until end of treatment (week 24; LSMD [95% CI]: -0.29 [-0.60, 0.03]; $P = .0760$) (Figure 4, A; see Table E5 in this article's Online Repository at www.jaci-inpractice.org). In VENTURE, dupilumab vs placebo-treated patients with allergic asthma showed significantly greater reductions from baseline in ACQ-5 score as early as week 2, and a mean score improvement >0.5 by week 24 (LSMD [95% CI]: -0.61 [-1.01, -0.22]; $P = .0029$). Numerically greater improvements were observed in patients without evidence of allergic asthma at week 24 (LSMD [95% CI]:

–0.40 [–0.83, 0.02]; $P = .0600$) (Figure 4, A; see Table E5 in this article’s Online Repository at www.jaci-inpractice.org).

Similarly, significantly greater improvements from baseline in AQLQ global score for dupilumab compared with placebo were seen at week 24 in patients with allergic asthma in both P2B (LSMD [95% CI]: 0.34 [0.08, 0.61]; $P = .0112$) and VENTURE (LSMD [95% CI]: 0.43 [0.04, 0.81]; $P = .0315$). There were also numerically greater improvements in AQLQ scores in patients without evidence of allergic asthma in both studies at week 24 (P2B; LSMD [95% CI]: 0.35 [–0.01, 0.71], $P = .0548$; VENTURE: LSMD [95% CI]: 0.34 [–0.03, 0.70], $P = .0706$) (Figure 4, B; see Table E5 in this article’s Online Repository at www.jaci-inpractice.org).

Type 2 biomarkers

Dupilumab vs placebo significantly reduced total IgE from baseline as early as week 4 in patients with or without evidence of allergic asthma in both studies; these reductions were sustained over the 24-week treatment period (Figure 5, A; see Table E6 in this article’s Online Repository at www.jaci-inpractice.org), with median change (95% CI) in total IgE from baseline in response to dupilumab treatment at week 24 in patients with (P2B: –152 IU/mL [–178, –119]; VENTURE: –189 IU/mL [–269, –111]) compared to those without evidence of allergic asthma (P2B: –45 IU/mL [–63.00, –9.00]; VENTURE to –67.5 IU/mL [–100, –42]) (all $P < .001$).

In patients with or without allergic asthma, significantly greater improvements in FeNO were seen for dupilumab vs placebo throughout both studies (Figure 5, B; see Table E7 in this article’s Online Repository at www.jaci-inpractice.org).

Similarly, dupilumab rapidly reduced serum TARC levels, with a significant difference vs placebo from week 2 in P2B and week 4 in VENTURE for patients with or without evidence of allergic asthma (Figure 5, C; see Table E8 in this article’s Online Repository at www.jaci-inpractice.org).

Specific IgE in patients with allergic asthma

In patients who met the criteria for allergic asthma and were positive for a given allergen at baseline, significant reductions vs placebo in allergen-specific IgE were observed at week 24 in both studies for all aeroallergens in VENTURE (Figure 6). Due to low patient numbers, results for *Aspergillus fumigatus* (placebo n = 5; dupilumab n = 7) and Oriental cockroach (placebo n = 4; dupilumab n = 5) in P2B and for *Cladosporium herbarum/hormodendrum* (placebo n = 3; dupilumab n = 9) in VENTURE were excluded. Data from VENTURE indicated that differences for dupilumab vs placebo were seen during treatment from as early as week 4 for some aeroallergens (Figure E1 available in this article's Online Repository at www.jaci-inpractice.org).

DISCUSSION

In this post-hoc analysis of the P2B and phase 3 LIBERTY ASTHMA VENTURE studies dupilumab reduced severe exacerbation rates; improved pre-bronchodilator FEV₁, pre-BD FEV₁/FVC ratio, asthma control, and asthma-related quality of life (QoL); and led to reductions in most type 2 biomarkers (IgE, FeNO, TARC) in patients with or without evidence of allergic asthma. Additionally, dupilumab significantly reduced OCS use vs placebo in patients with OCS-dependent severe asthma in VENTURE, irrespective of allergic status.

These results are consistent with those previously observed in patients with moderate-to-severe asthma enrolled in the QUEST study.¹⁷ Findings from all three studies support the important roles of IL-4 and IL-13 in type 2 inflammation in patients with or without evidence of allergic asthma, and the underlying impact of both cytokines in asthma pathogenesis.²¹ In line with its mode of action, dupilumab suppressed both total IgE and allergen-specific IgE in patients with allergic asthma, and also reduced IgE in patients not meeting allergic asthma criteria.^{4,22} This is an important consideration, as the definition of allergic asthma for this analysis was based on a serum total IgE level ≥ 30 IU/mL and positive allergen-specific IgE for at least one of the tested aeroallergens (i.e., specific IgE ≥ 0.35

kU/L). As not every potential allergen could be tested, the group without evidence of allergic asthma may have included patients with allergic asthma who were not sensitized to any of the allergens tested in the study. The reduction in serum IgE in patients with or without evidence of allergic asthma continued progressively throughout the treatment period, indicating a benefit of longer-term treatment with dupilumab. The observed efficacy in patients both with and without allergic asthma indicates that baseline IgE level is not a relevant biomarker when considering the suitability of dupilumab for individual patients, with key biomarkers being blood eosinophil counts and FeNO.²³

While significant improvements in rates of severe exacerbations were observed in both studies in patients with or without evidence of allergic asthma and in multiple other outcome measures for certain subgroups, numerical differences vs placebo were observed in change from baseline FEV₁ in VENTURE-patients with allergic asthma, but these did not reach statistical significance, possibly due to the relatively small sample size and the associated reduction in statistical power. Similarly, while there was a trend toward improvement vs placebo in ACQ-5 score in patients without evidence of allergic asthma in P2B, these differences were not statistically significant. At week 24, significant improvements vs placebo in asthma-related QoL were only observed in patients with allergic asthma. As with the other measures, there was a trend favoring dupilumab treatment vs placebo in patients without evidence of allergic asthma. The benefits of dupilumab on asthma control and HRQoL in patients in P2B and VENTURE have been demonstrated for the overall study populations previously.^{24,25} We hypothesize that determination of asthma control and QoL using a different test (such as the St Georges Respiratory Questionnaire [SGRQ] with increased sensitivity for detecting changes) and a larger sample size could have resulted in statistical significance in the analysis of these patients with severe asthma.

The results of this post-hoc analysis, and that of a similar analysis in patients with moderate-to-severe, uncontrolled asthma from the phase 3 QUEST study,¹⁷ highlight the benefits of reducing underlying type 2 inflammation in those patients, regardless of their allergic status. Another post-hoc analysis of QUEST also showed that dupilumab was

effective in patients with uncontrolled, moderate-to-severe asthma and comorbid perennial allergic rhinitis.²⁶ Strengths of this analysis include large study populations from randomized, double-blind, placebo-controlled clinical trials, and inclusion of patients irrespective of baseline IgE levels. As this analysis was performed post hoc, the trials were not specifically designed for assessment of these subgroups, and are subject to the same potential confounders and biases as other post-hoc analyses. Criteria for allergic asthma were based on threshold total serum IgE level and specific IgE levels against at least one of the tested aeroallergens. As the test panel did not include all allergens to which patients with allergic asthma may be sensitized, some patients enrolled in the two studies who were allergic to other aeroallergens may have been misclassified into the subgroup without evidence of allergic asthma.

In summary, treatment with dupilumab reduced rates of severe exacerbations and improved lung function, asthma control, and QoL in patients with or without evidence of allergic asthma. Biomarkers of type 2 inflammation were reduced in both subgroups across the studies. The findings from this analysis, and a similar analysis of a separate study in patients with moderate-to-severe uncontrolled asthma, indicate that dupilumab is beneficial in reducing the clinical burden of disease in patients both with and without evidence of allergic asthma.

463 **Acknowledgments**

464 Medical writing/editorial assistance provided by Nevena Krstic, PhD, of Excerpta Medica,
465 funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

466

REFERENCES

1. Kaur R, Chupp G. Phenotypes and endotypes of adult asthma: moving toward precision medicine. *J Allergy Clin Immunol* 2019;144:1-12.
2. Chen L, Grabowski KA, Xin JP, Coleman J, Huang Z, Espiritu B, et al. IL-4 induces differentiation and expansion of Th2 cytokine-producing eosinophils. *J Immunol* 2004;172:2059-66.
3. Poulsen LK, Hummelshoj L. Triggers of IgE class switching and allergy development. *Ann Med* 2007;39:440-56.
4. Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. *Nat Rev Drug Discov* 2016;15:35-50.
5. Rael EL, Lockey RF. Interleukin-13 signaling and its role in asthma. *World Allergy Organ J* 2011;4:54-64.
6. Wirnsberger G, Hebenstreit D, Posselt G, Horejs-Hoeck J, Duschl A. IL-4 induces expression of TARC/CCL17 via two STAT6 binding sites. *Eur J Immunol* 2006;36:1882-91.
7. Sekiya T, Yamada H, Yamaguchi M, Yamamoto K, Ishii A, Yoshie O, et al. Increased levels of a TH2-type CC chemokine thymus and activation-regulated chemokine (TARC) in serum and induced sputum of asthmatics. *Allergy* 2002;57:173-7.
8. Ricciardolo FLM. Multiple roles of nitric oxide in the airways. *Thorax* 2003;58:175-82.
9. Froidure A, Mouthuy J, Durham SR, Chanez P, Sibille Y, Pilette C. Asthma phenotypes and IgE responses. *Eur Respir J* 2016;47:304-19.
10. Platts-Mills TA. The role of immunoglobulin E in allergy and asthma. *Am J Respir Crit Care Med* 2001;164:S1-5.
11. Macdonald LE, Karow M, Stevens S, Auerbach W, Poueymirou WT, Yasenchak J, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. *Proc Natl Acad Sci U S A* 2014;111:5147-52.

12. Murphy AJ, Macdonald LE, Stevens S, Karow M, Dore AT, Pobursky K, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. *Proc Natl Acad Sci U S A* 2014;111:5153-8.
13. European Medicines Agency. Dupixent® (dupilumab). Summary of product characteristics. Available from: https://ec.europa.eu/health/documents/community-register/2019/20190801145601/anx_145601_en.pdf. Accessed October 4, 2021.
14. US Food and Drug Administration 2019. Dupixent® (dupilumab). Highlights of prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761055s014lbl.pdf. Accessed October 4, 2021.
15. Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β 2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. *Lancet* 2016;388:31-44.
16. Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. *N Engl J Med* 2018;378:2475-85.
17. Corren J, Castro M, O'Riordan T, Hanania NA, Pavord ID, Quirce S, et al. Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma. *J Allergy Clin Immunol Pract* 2020;8:516-26.
18. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention; 2009. Available from: <https://ginasthma.org/wp-content/uploads/2019/01/2009-GINA.pdf>. Accessed October 4, 2021.
19. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention; 2014. Available from: <https://ginasthma.org/wp-content/uploads/2019/01/2014-GINA.pdf>. Accessed October 4, 2021.
20. Omalizumab (Xolair®) Prescribing information; July 2021. Available from: https://www.gene.com/download/pdf/xolair_prescribing.pdf. Accessed October 4, 2021.

21. Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. *Expert Rev Clin Immunol* 2017;13:425-37.
22. Le Floch A, Allinne J, Nagashima K, Scott G, Birchard D, Asrat S, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R α antibody, is required to broadly inhibit type 2 inflammation. *Allergy* 2020;75:1188-204.
23. Brusselle GG, Koppelman GH. Biological Therapies for Severe Asthma. *New Engl J Med* 2022;386:157-71.
24. Corren J, Castro M, Chanez P, Fabbri L, Joish VN, Amin N, et al. Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma. *Ann Allergy Asthma Immunol* 2019;122:41-9.e2.
25. Ford LB, Rabe KF, Wolfe RN, Quirce S, Rice MS, Rowe P, et al. Dupilumab improved asthma control and health-related quality of life in patients with oral-corticosteroid-dependent severe asthma in the phase 3 LIBERTY ASTHMA VENTURE Study. *Am J Respir Crit Care Med* 2019;199:A2666.
26. Busse WW, Maspero JF, Lu Y, Corren J, Hanania NA, Chipps BE, et al. Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis. *Ann Allergy Asthma Immunol* 2020;125:565-76.e1.

FIGURE LEGENDS

FIGURE 1. Annualized severe exacerbation rates over time in (A) the phase 2b dose ranging, and (B) VENTURE studies in patients meeting and not meeting criteria for allergic asthma (ITT population). * $P < .05$, ** $P < .01$, *** $P < .001$; vs placebo. *ITT*, intent-to-treat.

FIGURE 2. Percentage reduction in OCS from baseline over the course of VENTURE in OCS-dependent severe asthma patients meeting and not meeting criteria for allergic asthma (ITT population). * $P < .05$, ** $P < .01$, *** $P < .001$; vs placebo. *OCS*, Oral corticosteroids. *ITT* intent-to-treat.

FIGURE 3. Change from baseline in (A) pre-bronchodilator FEV₁ and (B) pre-bronchodilator FEV₁/FVC ratio over time in patients meeting and not meeting criteria for allergic asthma (ITT population). **P* < .05, ***P* < .01, ****P* < .001; vs placebo. FEV₁, forced expiratory volume in one second; FVC, forced vital capacity.

FIGURE 4. Change from baseline in (A) ACQ-5 score and (B) AQLQ score in patients meeting and not meeting criteria for allergic asthma (ITT population). **P* < .05, ***P* < .01, ****P* < .001; vs placebo. FEV₁, forced expiratory volume in one second; FVC, forced vital capacity.

FIGURE 5. Change from baseline in (A) total IgE, (B) FeNO, and (C) TARC in patients meeting and not meeting criteria for allergic asthma (exposed population). **P* < .05, ***P* < .01, ****P* < .001; vs placebo. FeNO, Fractional exhaled nitric oxide; IgE, immunoglobulin E, TARC, Thymus and activation-regulated chemokine.

FIGURE 6. Median percent changes from baseline at week 24 with 95% confidence intervals in specific IgE in the allergic asthma subgroup with baseline serum specific-IgE levels ≥0.35 kU/mL for each allergen (exposed population) in the (A) phase 2b dose ranging study and in the (B) VENTURE study. **P* < .05, ***P* < .01, ****P* < .001; vs placebo. Due to low patient numbers, in P2B, results for *Aspergillus fumigatus* (placebo n = 5; dupilumab n = 7) and Oriental cockroach (placebo n = 4; dupilumab n = 5) and in VENTURE, results for *Cladosporium herbarum/hormodendrum* (placebo n = 3; dupilumab n = 9) were excluded. IgE, immunoglobulin E.

TABLES and FIGURES

TABLE I. Baseline characteristics of patients meeting and not meeting criteria for allergic asthma in the phase 2b and VENTURE study (ITT population)

	Phase 2b (24 weeks)				Phase 3 VENTURE (24 weeks)			
	Allergic asthma		Did not meet criteria for allergic asthma		Allergic asthma		Did not meet criteria for allergic asthma	
	Placebo (N = 95)	Combined dupilumab (N = 176)	Placebo (N = 63)	Combined dupilumab (N = 131)	Placebo (N = 40)	Dupilumab 300 mg q2w (N = 46)	Placebo (N = 67)	Dupilumab 300 mg q2w (N = 57)
Age, mean (SD), years	47.6 (12.5)	46.6 (13.5)	51.0 (13.0)	52.7 (11.4)	46.5 (14.5)	47.7 (14.5)	53.3 (11.1)	55.3 (9.3)
Female, n (%)	56 (58.9)	105 (59.7)	48 (76.2)	94 (71.8)	20 (50.0)	29 (63.0)	45 (67.2)	33 (57.9)
BMI, mean (SD), kg/m ²	29.00 (6.86)	29.69 (6.12)	29.37 (5.65)	29.51 (6.15)	29.11 (5.90)	29.81 (6.66)	30.16 (6.07)	28.13 (5.16)
Age at asthma onset, mean (SD), years	21.6 (16.9)	21.9 (18.1)	35.2 (16.8)	34.0 (15.1)	24.9 (16.8)	24.2 (19.3)	35.5 (14.9)	36.9 (16.6)
High-dose ICS use, n (%)	43 (45.7)	85 (49.4)	34 (55.7)	69 (55.2)	40 (100)	46 (100)	67 (100)	57 (100)

	Phase 2b (24 weeks)				Phase 3 VENTURE (24 weeks)			
	Allergic asthma		Did not meet criteria for allergic asthma		Allergic asthma		Did not meet criteria for allergic asthma	
	Placebo (N = 95)	Combined dupilumab (N = 176)	Placebo (N = 63)	Combined dupilumab (N = 131)	Placebo (N = 40)	Dupilumab 300 mg q2w (N = 46)	Placebo (N = 67)	Dupilumab 300 mg q2w (N = 57)
With ongoing atopic medical condition, n (%) (self-reported)	75 (79.8)	131 (75.3)	38 (63.3)	91 (70.5)	37 (92.5)	44 (95.7)	40 (59.7)	30 (52.6)
Atopic dermatitis	9 (9.6)	11 (6.3)	3(5.0)	9 (7.0)	7 (17.5)	6 (13.0)	1 (1.5)	2 (3.5)
Allergic rhinitis	66 (70.2)	114 (65.5)	33 (55.0)	73 (56.6)	26 (65.0)	30 (65.2)	35 (52.2)	26 (45.6)
Food allergy	13 (13.8)	20 (11.5)	2 (3.3)	8 (6.2)	6 (15.0)	5 (10.9)	4 (6.0)	4 (7.0)
Hives	6 (6.4)	12 (6.9)	2 (3.3)	5 (3.9)	2 (5.0)	3 (6.5)	2 (3.0)	2 (3.5)
Severe asthma exacerbations in the past year, mean (SD), n	1.89 (1.32)	2.05 (1.65)	2.84 (3.10)	2.21 (2.26)	2.43 (2.36)	2.50 (2.55)	2.01 (2.16)	1.61 (1.51)

	Phase 2b (24 weeks)				Phase 3 VENTURE (24 weeks)			
	Allergic asthma		Did not meet criteria for allergic asthma		Allergic asthma		Did not meet criteria for allergic asthma	
	Placebo (N = 95)	Combined dupilumab (N = 176)	Placebo (N = 63)	Combined dupilumab (N = 131)	Placebo (N = 40)	Dupilumab 300 mg q2w (N = 46)	Placebo (N = 67)	Dupilumab 300 mg q2w (N = 57)
Pre-BD FEV ₁ , L, mean (SD)	1.90 (0.58)	1.90 (0.57)	1.71 (0.49)	1.72 (0.45)	1.62 (0.66)	1.59 (0.46)	1.63 (0.58)	1.49 (0.58)
Percent predicted FEV ₁ , %	61.22 (10.48)	60.88 (10.77)	60.56 (11.13)	61.14 (10.58)	49.90 (15.82)	52.83 (13.61)	54.36 (14.59)	50.68 (16.57)
FEV ₁ /FVC ratio, %, mean (SD)	64.07 (9.48)	65.20 (9.49)	64.12 (10.51)	63.33 (9.75)	58.26 (13.02)	61.43 (9.78)	58.91 (10.23)	56.71 (11.41)
Daily OCS dose at Visit 1 (i.e., pre-optimization), mg/day, mean (SD)	-	-	-	-	11.76 (5.77)	11.79 (5.91)	11.87 (6.21)	11.79 (6.83)
Optimized daily OCS dose at baseline (mg/day)	-	-	-	-	12.31 (6.66)	10.71 (5.62)	11.42 (6.11)	10.79 (6.16)
ACQ-5 score,* mean (SD)	2.62 (0.80)	2.73 (0.82)	2.79 (0.78)	2.82 (0.83)	2.52 (1.13)	2.40 (1.22)	2.62 (1.07)	2.43 (1.26)

	Phase 2b (24 weeks)				Phase 3 VENTURE (24 weeks)			
	Allergic asthma		Did not meet criteria for allergic asthma		Allergic asthma		Did not meet criteria for allergic asthma	
	Placebo (N = 95)	Combined dupilumab (N = 176)	Placebo (N = 63)	Combined dupilumab (N = 131)	Placebo (N = 40)	Dupilumab 300 mg q2w (N = 46)	Placebo (N = 67)	Dupilumab 300 mg q2w (N = 57)
AQLQ score, [†] mean (SD)	4.24 (1.11)	4.10 (1.13)	3.93 (1.07)	3.79 (1.12)	4.34 (1.16)	4.35 (1.21)	4.30 (1.10)	4.40 (1.26)
Blood eosinophil count, GIGA/L, median (Q1-Q3)	0.260 (0.160-0.410)	0.250 (0.170-0.405)	0.240 (0.150-0.440)	0.280 (0.160-0.510)	0.265 (0.110-0.565)	0.240 (0.170-0.350)	0.220 (0.120-0.410)	0.350 (0.150-0.560)
FeNO, ppb, median (Q1-Q3)	32.0 (16.0-49.0)	27.5 (16.0-53.0)	24.5 (16.0-42.0)	30.0 (15.0-47.0)	30.0 (21.0-55.0)	23.0 (13.0-39.0)	23.5 (14.5-57.5)	36.5 (17.5-54.5)
Total serum IgE, IU/mL, median (Q1-Q3)	302.0 (138.0-523.0)	293.0 (129.5-646.0)	94.5 (31.0-216.0)	90.0 (25.0-178.0)	340.0 (187.0-820.0)	305.0 (150.0-941.0)	68.0 (23.0-164.0)	131.0 (48.0-244.0)
Serum TARC, pg/mL, median (Q1-Q3)	377.28 (267.87- 577.82)	423.31 (305.64- 641.77)	330.58 (228.79- 502.92)	402.64 (282.77- 598.68)	291.00 (161.00-550.00)	234.50 (134.00- 475.00)	281.50 (170.00- 402.00)	275.00 (232.00- 448.00)


Phase 2b (24 weeks)				Phase 3 VENTURE (24 weeks)			
Allergic asthma		Did not meet criteria for allergic asthma		Allergic asthma		Did not meet criteria for allergic asthma	
Placebo (N = 95)	Combined dupilumab (N = 176)	Placebo (N = 63)	Combined dupilumab (N = 131)	Placebo (N = 40)	Dupilumab 300 mg q2w (N = 46)	Placebo (N = 67)	Dupilumab 300 mg q2w (N = 57)

BD, bronchodilator; *BL*, baseline; *ACQ-5*, Asthma Control Questionnaire – 5; *AQLQ*, Asthma Quality of Life Questionnaire; *FeNO*, fractional exhaled nitric oxide; *FEV₁*, forced expiratory volume in one second; *ICS*, inhaled corticosteroid; *IgE*, immunoglobulin E; *OCS*, oral corticosteroid; *Q*, quartile; *q2w*, every 2 weeks; *SD*, standard deviation; *TARC*, thymus and activation-regulated chemokine.

*ACQ-5 scores range between 0 (totally controlled) and 6 (severely uncontrolled).

†AQLQ(S) scores are rated on a 7-point Likert-like scale (7 = not impaired at all - 1 = severely impaired).

A) Phase 2b study



B) Phase 3 VENTURE study






Figure 2

—■— Placebo —●— Dupilumab 300 mg q2w

Allergic asthma



Did not meet the criteria for allergic asthma



No. of patients								
		BL	4	8	12	16	20	24
Placebo	40	40	40	40	40	40	40	40
Dupilumab 300 mg q2w	46	46	45	45	45	45	45	45

67	67	67	67	67	67	66
57	57	57	56	56	56	56

A) Change from baseline in pre-bronchodilator FEV₁



Journal Pre-proof

Phase 2b study

Placebo Combined dupilumab 200/300 mg q2w

Allergic asthma

Did not meet the criteria for allergic asthma



No. of patients

Placebo	95	92	95	93	93	92	90	90
Combined dupilumab 200/300 mg q2w	176	173	174	171	169	168	164	165

No. of patients



Placebo	63	61	62	59	60	59	58	56
Combined dupilumab 200/300 mg q2w	131	128	128	122	122	121	121	121

Phase 3 VENTURE study

Placebo Dupilumab 300 mg q2w

Allergic asthma

Did not meet the criteria for allergic asthma



No. of patients


Placebo	40	39	37	40	40	39	39	40	39
Dupilumab 300 mg q2w	46	46	44	45	45	44	43	44	44

No. of patients

Placebo	67	65	67	66	67	66	67	67	65
Dupilumab 300 mg q2w	57	55	54	56	55	55	55	56	53

Figure 3 (B)

B) Change from baseline in pre-bronchodilator FEV₁/FVC ratio
Phase 2b study



Phase 3 VENTURE study





Figure 4 (A)

A) Change from baseline in Δ CO-5 score
Phase 2b study



Phase 3 VENTURE study






Figure 4 (B)

B) Change from baseline in AQLQ score
Phase 2b study




Phase 3 VENTURE study




A) Change from baseline in total IgE

Phase 2b study




Phase 3 VENTURE study




B) Change from baseline in FeNO

Phase 2b study




Phase 3 VENTURE study




C) Change from baseline in TARC

Phase 2b study




Phase 3 VENTURE study




Phase 2b study

■ Placebo ■ Combined dupilumab 200/300 mg q2w




Phase 3 VENTURE study

■ Placebo ■ Dupilumab 300 mg q2w



B) *Dermatophagoides pteronyssinus*

Phase 2b study



No. of patients


Placebo 25

25

Dupilumab 46

44

Phase 3 VENTURE study



12

11

12

12

12

12

12


12

11

12

C) *Alternaria tenuis/alternata*

Phase 2b study



No. of patients


Placebo 19

19

Dupilumab 37

33

Phase 3 VENTURE study



8

7

8

8

8

12

12


12

12

12

B) *Demodex* *farina*

Phase 2b study



No. of patients


Placebo 46

42

Dupilumab 93

86

Phase 3 VENTURE study



13

13

13

14

13

17

16


16

17

16

E) Degradation of *D. farinae*

Phase 2b study




No. of patients

Placebo 48
Dupilumab 820

49

94

Phase 3 VENTURE study



19

28

13

24

19

28

12


25

13

26

F) German cockroach

Phase 2b study




No. of patients

Placebo	28	27
Dupilumab	48	43

G) Oriental cockroach

Phase 3 VENTURE study




No. of patients

Placebo	11	10	11	10	11
Dupilumab	18	17	18	17	18

H) *Cladosporium herbarum*/hormodendrum

Phase 2b study




No. of patients

Placebo	8	8
Dupilumab	25	21

I) *Aspergillus fumigatus*

Phase 3 VENTURE study




No. of patients

Placebo	17	16	16	16	16
Dupilumab	15	15	14	14	15

A) *Dermatophagoides farinae*

Phase 2b study




No. of patients

Placebo	46
Dupilumab	82

42
74

Phase 3 VENTURE study



13	13	13	12	13
17	17	16	17	16

ONLINE REPOSITORY MATERIALS

Dupilumab Efficacy in Patients with Uncontrolled or Oral Corticosteroid-Dependent Allergic and Non-allergic Asthma

Guy Brusselle, MD^a, Santiago Quirce, MD^b, Alberto Papi, MD^c, Piotr Kuna, MD^d, Bradley E. Chipps, MD^e, Nicola A. Hanania, MD^f, Michael Blaiss, MD^g, Jérôme Msihid, MS^h, Juby A. Jacob-Nara, MDⁱ, Yamo Deniz, MD^j, Paul J. Rowe, MDⁱ, Rebecca Gall, MD^j, Benjamin Ortiz, MD^j, Michel Djandji, MD^k, and Amr Radwan, MBBChir FFPMⁱ

Ghent, Belgium; Madrid, Spain; Ferrara, Italy; Łódź, Poland; Sacramento, CA, USA; Houston, TX, USA; Augusta, GA, USA; Chilly-Mazarin, France; Bridgewater, NJ, USA; Tarrytown, NY, USA; Cambridge, MA, USA

^aGhent University Hospital, Ghent, Belgium

^bHospital Universitario La Paz, IdiPAZ, CIBERES, Madrid, Spain

^cRespiratory Medicine Unit, University of Ferrara, S. Anna University Hospital, Ferrara, Italy

^dMedical University of Łódź, Łódź, Poland

^eCapital Allergy and Respiratory Disease Center, Sacramento, CA, USA

^fSection of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA

^gMedical College of Georgia at Augusta University, Augusta, GA, USA

^hSanofi, Chilly-Mazarin, France

ⁱSanofi, Bridgewater, NJ, USA

^jRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA

^kSanofi, Cambridge, MA, USA

This appendix has been provided by the authors to give readers additional information about their work.

27

28 **Contents**

29	ONLINE REPOSITORY MATERIALS	0
30	Dupilumab Efficacy in Patients with Uncontrolled or Oral Corticosteroid-Dependent Allergic	
31	and Non-allergic Asthma	0
32	TABLE E1. Baseline-specific IgE allergen concentrations in patients with and without evidence of	
33	an allergic asthma phenotype	3
34	TABLE E2. Percent reduction in OCS use from baseline to week 24 (VENTURE) in OCS-	
35	dependent severe asthma patients meeting and not meeting criteria for allergic asthma (ITT	
36	population)	6
37	TABLE E3. Change from baseline in FEV ₁ at weeks 2 and 24 in patients meeting and not	
38	meeting criteria for allergic asthma (ITT population)	8
39	TABLE E4. Change from baseline in FEV ₁ /FVC at weeks 2 and 24 in patients meeting and not	
40	meeting criteria for allergic asthma	9
41	TABLE E5. Change from baseline in ACQ-5* and AQLQ [†] scores at weeks 2 and 24 in patients	
42	meeting and not meeting criteria for allergic asthma	11
43	TABLE E6. Change from baseline in serum IgE at weeks 4 and 24 in patients meeting and not	
44	meeting criteria for allergic asthma (exposed population)	13
45	TABLE E7. Change from baseline in FeNO at weeks 2 and 24 in patients meeting and not	
46	meeting criteria for allergic asthma (exposed population)	15
47	TABLE E8. Change from baseline in serum TARC at weeks 4 and 24 in patients meeting and not	
48	meeting criteria for allergic asthma (exposed population)	17
49	FIGURE E1. Percent Change from baseline in specific IgE (95%CI) against (A)	
50	<i>Dermatophagoides farinae</i> , (B) <i>Dermatophagoides pteronyssinus</i> , (C) <i>Alternaria tenuis/alternata</i> ,	
51	(D) cat dander, (E) dog dander, (F) German cockroach, (G) oriental cockroach, (H) <i>Cladosporium</i>	

52 *herbarum/hormodendrum*, (I) *Aspergillus fumigatus* in exposed patients with baseline serum
53 specific-IgE levels ≥ 0.35 kU/mL for each allergen and meeting criteria for allergic asthma..... 19

54

Journal Pre-proof

55 **TABLE E1.** Baseline-specific IgE allergen concentrations in patients with and without evidence of an allergic asthma phenotype

	Phase 2B (24 weeks)				Phase 3 VENTURE (24 weeks)			
	Allergic asthma		Did not meet criteria for allergic asthma		Allergic asthma		Did not meet criteria for allergic asthma	
	Placebo (N = 95)	Combined dupilumab (N = 176)	Placebo (N = 63)	Combined dupilumab (N = 131)	Placebo (N = 40)	Dupilumab 300 mg q2w (N = 46)	Placebo (N = 67)	Dupilumab 300 mg q2w (N = 57)
<i>Aspergillus fumigatus</i> ≥0.35 KU/L at BL	5 (5.3)	7 (4.0)	0	0	17 (42.5)	15 (32.6)	0	0
KU/L, median (Q1-Q3)	0.05 (0.05-1.33)	0.05 (0.05-0.40)	0.05 (0.05-0.05)	0.05 (0.05-0.05)	0.12 (0.05-0.91)	0.05 (0.05-0.49)	0.05 (0.05-0.05)	0.05 (0.05-0.05)
<i>Alternaria tenuis/alternata</i> ≥0.35 KU/L at BL	19 (20.0)	37 (21.0)	4 (6.3)	0	8 (20.0)	12 (26.1)	0	0
KU/L, median (Q1:Q3)	0.05 (0.05-0.16)	0.05 (0.05-0.18)	0.05 (0.05-0.05)	0.05 (0.05-0.05)	0.05 (0.05-0.19)	0.05 (0.05-0.35)	0.05 (0.05-0.05)	0.05 (0.05-0.05)
<i>Cladosporium herbarum/hormodendrum</i> ≥0.35 KU/L at BL	8 (8.4)	25 (14.2)	2 (3.2)	0	3 (7.5)	9 (19.6)	0	0
KU/L, median (Q1-Q3)	0.05 (0.05-0.11)	0.05 (0.05-0.15)	0.05 (0.05-0.05)	0.05 (0.05-0.05)	0.05 (0.05-0.05)	0.05 (0.05-0.16)	0.05 (0.05-0.05)	0.05 (0.05-0.05)
<i>Dermatophagoides farinae</i> ≥0.35 KU/L at BL	46 (48.4%)	82 (46.6%)	1 (1.6%)	3 (2.3%)	13 (32.5%)	17 (37.0%)	1 (1.5%)	0

	Phase 2B (24 weeks)				Phase 3 VENTURE (24 weeks)			
	Allergic asthma		Did not meet criteria for allergic asthma		Allergic asthma		Did not meet criteria for allergic asthma	
	Placebo (N = 95)	Combined dupilumab (N = 176)	Placebo (N = 63)	Combined dupilumab (N = 131)	Placebo (N = 40)	Dupilumab 300 mg q2w (N = 46)	Placebo (N = 67)	Dupilumab 300 mg q2w (N = 57)
KU/L, median (Q1-Q3)	1.38 (0.21-14.90)	1.35 (0.18-8.48)	0.05 (0.05-0.05)	0.05 (0.05-0.05)	1.19 (0.15-9.08)	0.48 (0.05-2.03)	0.05 (0.05-0.05)	0.05 (0.05-0.05)
<i>Dermatophagoides pteronyssinus</i> ≥0.35 KU/L at BL	25 (26.3%)	46 (26.1%)	0	1 (0.8%)	12 (30.0%)	12 (26.1%)	0	0
KU/L, median (Q1-Q3)	4.08 (0.55-31.60)	3.46 (0.68-21.50)	0.05 (0.05-0.13)	0.05 (0.05-0.11)	1.69 (0.05-20.70)	1.66 (0.22-19.00)	0.05 (0.05-0.05)	0.05 (0.05-0.05)
Cat dander ≥0.35 KU/L at BL	54 (56.8%)	95 (54.0%)	1 (1.6%)	3 (2.3%)	15 (37.5%)	21 (45.7%)	1 (1.5%)	0
KU/L, median (Q1-Q3)	0.65 (0.05-5.23)	0.59 (0.05-3.89)	0.05 (0.05-0.05)	0.05 (0.05-0.05)	0.13 (0.05-2.87)	0.18 (0.05-5.09)	0.05 (0.05-0.05)	0.05 (0.05-0.05)
Dog dander ≥0.35 KU/L at BL	51 (53.7%)	100 (56.8%)	1 (1.6%)	2 (1.5%)	19 (47.5%)	26 (56.5%)	1 (1.5%)	0
KU/L, median (Q1-Q3)	0.49 (0.10-2.52)	0.54 (0.08-4.10)	0.05 (0.05-0.05)	0.05 (0.05-0.05)	0.41 (0.05-2.02)	0.51 (0.10-5.26)	0.05 (0.05-0.05)	0.05 (0.05-0.05)
German cockroach* ≥0.35 KU/L at BL	28 (29.5%)	48 (27.3%)	0	0	-	-	-	-
KU/L, median (Q1-Q3)	0.22 (0.05-0.51)	0.16 (0.05-0.60)	0.05 (0.05-0.05)	0.05 (0.05-0.05)	-	-	-	-

	Phase 2B (24 weeks)				Phase 3 VENTURE (24 weeks)			
	Allergic asthma		Did not meet criteria for allergic asthma		Allergic asthma		Did not meet criteria for allergic asthma	
	Placebo (N = 95)	Combined dupilumab (N = 176)	Placebo (N = 63)	Combined dupilumab (N = 131)	Placebo (N = 40)	Dupilumab 300 mg q2w (N = 46)	Placebo (N = 67)	Dupilumab 300 mg q2w (N = 57)
Oriental cockroach ≥ 0.35 KU/L at BL	4 (4.2%)	5 (2.8%)	0	0	11 (27.5%)	18 (39.1%)	0	0
KU/L, median (Q1-Q3)	0.05 (0.05-0.37)	0.05 (0.05-0.11)	0.05 (0.05-0.05)	0.05 (0.05-0.05)	0.09 (0.05-0.40)	0.23 (0.05-1.22)	0.05 (0.05-0.05)	0.05 (0.05-0.05)

BL, baseline; q2w, every two weeks.

58 **TABLE E2.** Percent reduction in OCS use from baseline to week 24 (VENTURE) in OCS-dependent severe asthma patients meeting and not
 59 meeting criteria for allergic asthma (ITT population)

	Allergic asthma		Did not meet the criteria for allergic asthma	
	Placebo (n = 40)	Dupilumab 300 mg q2w (n = 46)	Placebo (n = 67)	Dupilumab 300 mg q2w (n = 57)
Proportion of patients achieving reduction in OCS at week 24				
Patients achieving a reduction of OCS dose to $\geq 50\%$ (%)	47.5	81.5	56.7	80.6
Adjusted probability of achieving the reduction (95% CI)	0.46 (0.30, 0.63)	0.80 (0.63, 0.90)	0.51 (0.37, 0.64)	0.82 (0.68, 0.91)
Odds ratio vs placebo (95% CI)		4.63 (1.69, 12.71)		4.43 (1.76, 11.13)
P value		.0029		.0015
Patients achieving a reduction of OCS dose to < 5 mg/day (%)	32.5	72.8	40.3	72.9
Adjusted probability of achieving the reduction (95% CI)	0.28 (0.15, 0.46)	0.69 (0.50, 0.83)	0.33 (0.21, 0.47)	0.70 (0.55, 0.82)
Odds ratio vs placebo (95% CI)		5.77 (2.08, 15.98)		4.84 (2.03, 11.53)
P value		.0008		.0004
Risk ratio vs placebo (95% CI)		1.93 (2.08, 15.98)		1.68 (1.2, 2.36)
P value		.0008		.0027
Patients achieving their maximum possible reduction of OCS dose per protocol	25.0%	52.8%	32.8%	52.8%
Adjusted probability of achieving the reduction (95% CI)	0.22 (0.11, 0.39)	0.46 (0.29, 0.64)	0.27 (0.17, 0.41)	0.48 (0.34, 0.63)
Odds ratio vs placebo (95% CI)		3.08 (1.16, 8.18)	-	2.48 (1.11, 5.54)
P value		.0240		.0266

Risk ratio vs placebo (95% CI)		1.91 (1.06, 3.43)		1.44 (0.95, 2.17)
<i>P</i> value		.0313		.0826
Patients no longer requiring OCS at week 24 in patients with baseline OCS dose ≤ 30 mg/day				
	25.0%	52.8%	31.8%	52.8%
Adjusted probability of achieving the reduction (95% CI)	0.22 (0.11, 0.39)	0.46 (0.29, 0.64)	0.26 (0.16, 0.39)	0.48 (0.33, 0.64)
Odds ratio vs placebo (95% CI)	-	3.08 (1.16, 8.18)	-	2.71 (1.18, 6.21)
<i>P</i> value		.0240		.0188
Risk ratio vs placebo (95% CI)		1.91 (1.06, 3.43)		1.43 (0.95, 2.16)
<i>P</i> value		.0313		.0851

BL, baseline; CI, confidence interval; LS, least squares; LSMD, LS mean difference; OCS, oral corticosteroid; SE, standard error; q2w, every 2 weeks

62 **TABLE E3.** Change from baseline in FEV₁ at weeks 2 and 24 in patients meeting and not meeting criteria for allergic asthma (ITT population)

	Phase 2B (24 weeks)				Phase 3 VENTURE (24 weeks)			
	Allergic asthma		Did not meet criteria for allergic asthma		Allergic asthma		Did not meet criteria for allergic asthma	
	Placebo (N = 95)	Combined dupilumab (N = 176)	Placebo (N = 63)	Combined dupilumab (N = 131)	Placebo (N = 40)	Dupilumab 300 mg q2w (N = 46)	Placebo (N = 67)	Dupilumab 300 mg q2w (N = 57)
FEV ₁ at BL, L, mean (SD)	1.90 (0.58)	1.90 (0.57)	1.71 (0.49)	1.72 (0.45)	1.62 (0.66)	1.59 (0.46)	1.63 (0.58)	1.49 (0.58)
Change from baseline in FEV₁ at week 2								
	n = 92	n = 173	n = 61	n = 128	n = 39	n = 46	n = 65	n = 55
LS mean (95% CI)	0.04 (-0.03, 0.10)	0.21 (0.16, 0.26)	0.12 (0.03, 0.21)	0.23 (0.16, 0.29)	0.03 (-0.13, 0.18)	0.18 (0.02, 0.34)	0.04 (-0.06, 0.13)	0.21 (0.11, 0.31)
LS mean difference vs placebo (95% CI)		0.18 (0.10, 0.26)		0.10 (0.00, 0.21)		0.15 (-0.06, 0.36)		0.17 (0.04, 0.30)
P value vs placebo		< .0001		.0564		.1517		.0097
Change from baseline in FEV₁ at week 24								
	n = 90	n = 165	n = 56	n = 121	n = 39	n = 44	n = 65	n = 53
LS mean (95% CI)	0.10 (0.02, 0.17)	0.25 (0.19, 0.30)	0.17 (0.06, 0.27)	0.33 (0.25, 0.40)	0.02 (-0.14, 0.19)	0.23 (0.06, 0.39)	0.01 (-0.09, 0.12)	0.23 (0.12, 0.35)
LS mean difference vs placebo (95% CI)		0.15 (0.06, 0.24)		0.16 (0.04, 0.28)		0.20 (-0.02, 0.43)		0.22 (0.07, 0.37)
P value vs placebo		.0011		.0104		.0710		.0046

63 BL, baseline; CI, confidence interval; FEV₁, fractional exhaled volume in one second; q2w, every two weeks; SD, standard deviation; SE, standard error.

64 **TABLE E4.** Change from baseline in FEV₁/FVC at weeks 2 and 24 in patients meeting and not meeting criteria for allergic asthma

	Phase 2B (24 weeks)				Phase 3 VENTURE (24 weeks)			
	Allergic asthma		Did not meet criteria for allergic asthma		Allergic asthma		Did not meet criteria for allergic asthma	
	Placebo	Combined	Placebo	Combined	Placebo	Dupilumab	Placebo	Dupilumab
	(N = 95)	dupilumab (N = 176)	(N = 63)	dupilumab (N = 131)	(N = 40)	300 mg q2w (N = 46)	(N = 67)	300 mg q2w (N = 57)
FEV ₁ /FVC at BL, %, mean (SD)	64.07 (9.48)	65.20 (9.49)	64.12 (10.51)	63.33 (9.75)	58.26 (13.02)	61.43 (9.78)	58.91 (10.23)	56.71 (11.41)
Change from baseline in FEV₁/FVC at week 2								
	n = 92	n = 173	n = 61	n = 128	n = 39	n = 46	n = 66	n = 55
LS mean (95% CI)	-0.19 (-1.41, 1.02)	2.16 (1.25, 3.06)	0.93 (-0.47, 2.33)	2.51 (1.49, 3.52)	-0.71 (-3.14, 1.73)	1.18 (-1.28, 3.63)	-0.01 (-1.97, 1.95)	1.70 (-0.36, 3.75)
LS mean difference vs placebo (95% CI)		2.35 (0.88, 3.82)		1.58 (-0.06, 3.21)		1.88 (-1.39, 5.15)		1.71 (-0.95, 4.37)
P value vs placebo		.0018		.0588		.2559		.2059
Change from baseline in FEV₁/FVC at week 24								
	n = 90	n = 165	n = 56	n = 121	n = 39	n = 44	n = 65	n = 53
LS mean (95% CI)	0.93 (-0.34, 2.20)	2.82 (1.88, 3.77)	1.36 (-0.34, 3.06)	4.02 (2.80, 5.23)	0.29 (-2.30, 2.88)	2.33 (-0.29, 4.94)	0.54 (-1.57, 2.66)	2.21 (-0.03, 4.45)

LS mean difference vs placebo	1.89	2.66	2.04	1.67
(95% CI)	(0.36, 3.43)	(0.64, 4.67)	(-1.47, 5.54)	(-1.25, 4.58)
<i>P</i> value vs placebo	.0159	.0101	.2509	.2599

BL, baseline; *CI*, confidence interval; *FEV*₁, fractional exhaled volume in one second; *q2w*, every two weeks; *SD*, standard deviation; *SE*, standard error.

65

66

67 **TABLE E5.** Change from baseline in ACQ-5⁺ and AQLQ⁺ scores at weeks 2 and 24 in patients meeting and not meeting criteria for allergic
 68 asthma

	Phase 2B (24 weeks)				Phase 3 VENTURE (24 weeks)			
	Allergic asthma		Did not meet criteria for allergic asthma		Allergic asthma		Did not meet criteria for allergic asthma	
	Placebo (N = 95)	Combined dupilumab (N = 176)	Placebo (N = 63)	Combined dupilumab (N = 131)	Placebo (N = 40)	Dupilumab 300 mg q2w (N = 46)	Placebo (N = 67)	Dupilumab 300 mg q2w (N = 57)
ACQ-5 at BL, mean (SD)	2.62 (0.80)	2.73 (0.82)	2.79 (0.78)	2.82 (0.83)	2.52 (1.13)	2.40 (1.22)	2.62 (1.07)	2.43 (1.26)
Change from baseline in ACQ-5 at week 2								
	n = 88	n = 166	n = 53	n = 124	n = 38	n = 43	n = 64	n = 52
LS mean (95% CI)	-0.71 (-0.89, - 0.54)	-0.85 (-0.98, - 0.72)	-0.71 (-0.94, - 0.49)	-0.78 (-0.94, - 0.62)	-0.03 (-0.26, 0.19)	-0.48 (-0.72, -0.25)	-0.37 (-0.56, -0.18)	-0.67 (-0.88, -0.46)
LS mean difference vs placebo (95% CI)		-0.14 (-0.35, 0.08)		-0.07 (-0.33, 0.20)		-0.45 (-0.76, -0.14)		-0.30 (-0.56, -0.04)
P value vs placebo		.2099		.6236		.0047		.0268
Change from baseline in ACQ-5 at week 24								
	n = 80	n = 158	n = 47	n = 121	n = 38	n = 44	n = 61	n = 52
LS mean (95% CI)	-1.14 (-1.35, - 0.94)	-1.50 (-1.65, - 1.35)	-1.15 (-1.42, - 0.88)	-1.43 (-1.62, - 1.25)	-0.49 (-0.78, -0.20)	-1.11 (-1.39, -0.82)	-0.62 (-0.91, -0.33)	-1.02 (-1.34, -0.70)

LS mean difference vs placebo (95% CI)	-0.35 (-0.60, -0.11)	-0.29 (-0.60, 0.03)	-0.61 (-1.01, -0.22)	-0.40 (-0.83, 0.02)				
P value vs placebo	.0045	.0760	.0029	.0600				
AQLQ at BL, mean (SD)	4.24 (1.11)	4.10 (1.13)	3.93 (1.07)	3.79 (1.12)	4.34 (1.16)	4.35 (1.21)	4.30 (1.10)	4.40 (1.26)

Change from baseline in AQLQ at week 12

	n = 84	n = 163	n = 51	n = 118	n = 39	n = 44	n = 66	n = 54
LS mean (95% CI)	0.76 (0.56, 0.95)	1.13 (0.98, 1.27)	0.95 (0.67, 1.24)	1.13 (0.93, 1.32)	0.72 (0.43, 1.02)	0.78 (0.48, 1.09)	0.46 (0.21, 0.71)	0.76 (0.48, 1.03)
LS mean difference vs placebo (95% CI)	-	0.37 (0.14, 0.61)	-	0.17 (-0.15, 0.49)	-	0.06 (-0.34, 0.46)	-	0.30 (-0.05, 0.64)
P value vs placebo		.0021		.2850		.7626		.0909

Change from baseline in AQLQ at week 24

	n = 80	n = 152	n = 47	n = 121	n = 39	n = 44	n = 61	n = 54
LS mean (SE)	0.91 (0.69, 1.13)	1.25 (1.09, 1.41)	0.83 (0.52, 1.14)	1.18 (0.97, 1.39)	0.52 (0.23, 0.80)	0.94 (0.65, 1.24)	0.54 (0.28, 0.80)	0.88 (0.59, 1.16)
LS mean difference vs placebo (95% CI)	-	0.34 (0.08, 0.61)	-	0.35 (-0.01, 0.71)	-	0.43 (0.04, 0.81)	-	0.34 (-0.03, 0.70)
P value vs placebo		.0112		.0548		.0315		.0706

69 ACQ-5, 5-item Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; BL, baseline; CI, confidence interval; q2w, every two weeks; SD, standard deviation; SE, standard error.

70 *ACQ-5 scores range between 0 (totally controlled) and 6 (severely uncontrolled).

71 †AQLQ(S) scores are rated on a 7-point Likert-like scale (7 = not impaired at all - 1 = severely impaired).

72 **TABLE E6.** Change from baseline in serum IgE at weeks 4 and 24 in patients meeting and not meeting criteria for allergic asthma (exposed
73 population)

	Phase 2B (24 weeks)				Phase 3 VENTURE (24 weeks)			
	Allergic asthma		Did not meet criteria for allergic asthma		Allergic asthma		Did not meet criteria for allergic asthma	
	Placebo (N = 95)	Combined dupilumab (N = 176)	Placebo (N = 62)	Combined dupilumab (N = 128)	Placebo (N = 40)	Dupilumab 300 mg q2w (N = 46)	Placebo (N = 67)	Dupilumab 300 mg q2w (N = 57)
BL serum IgE, IU/mL, mean (SD)	569.73 (896.15)	552.11 (682.19)	188.82 (244.39)	166.70 (279.91)	876.58 (1296.01)	699.87 (875.08)	153.92 (215.71)	220.61 (246.14)
Baseline, median (95% CI)	302.00 (222.0, 367.0)	293.00 (249.0, 370.0)	94.50 (57.0, 147.0)	88.00 (57.0, 113.0)	340.00 (262.0, 662.0)	305.00 (195.0, 611.0)	68.00 (38.0, 106.0)	131.00 (94.0, 182.0)
Q1-Q3	138.0-523.0	129.5-646.0	31.0-216.0	25.5-174.5	187.0-820.0	150.0-941.0	23.0-164.0	48.0-244.0
Change from baseline in total IgE at week 4, IU/mL								
	n = 94	n = 173	n = 61	n = 126	n = 38	n = 44	n = 65	n = 54
Median change from BL (95% CI)	-2.00 (-8.00, 8.00)	-23.00 (-32.00, -16.00)	0.50 (-2.00, 4.00)	-10.50 (-17.00, -6.00)	-27.50 (-42.00, -2.00)	-50.00 (-117.00, -29.00)	-3.00 (-9.00, -1.00)	-21.50 (-47.00, -11.00)
Q1-Q3	-26.0 to 29.0	-85.0 to -3.0	-5.0 to 20.0	-32.0 to -2.0	-81.0 to 10.0	-162.0 to -15.5	-22.0 to 3.0	-72.0 to -3.0
P value vs placebo		< .0001		< .0001		.0213		.0009

Change from baseline in total IgE at week 24, IU/mL

	n = 90	n = 164	n = 53	n = 121	n = 40	n = 44	n = 63	n = 56
Median change from BL	1.50	-152.00	0.00	-45.00	-35.50	-189.00	0.00	-67.50
(95% CI)	(-9.00, 27.00)	(-178.00, -119.00)	(-3.00, 8.00)	(-63.00, -29.00)	(-93.00, -6.00)	(-269.00, -111.00)	(-3.00, 3.00)	(-100.00, -42.00)
Q1-Q3	-41.0 to 86.0	-327.5 to -64.0	-6.0 to 17.0	-101.0 to -11.0	-170.5 to 0.0	-544.0 to -76.0	-16.0 to 15.0	-161.0 to -21.0
P value vs placebo		< .0001		< .0001		< .0001		< .0001

74

BL, baseline; CI, confidence interval; IgE, immunoglobulin E; Q, quartile; q2w, every two weeks; SD, standard deviation.

75 **TABLE E7.** Change from baseline in FeNO at weeks 2 and 24 in patients meeting and not meeting criteria for allergic asthma (exposed
 76 population)

	Phase 2B (24 weeks)				Phase 3 VENTURE (24 weeks)			
	Allergic asthma		Did not meet criteria for allergic asthma		Allergic asthma		Did not meet criteria for allergic asthma	
	Placebo (N = 95)	Combined dupilumab (N = 176)	Placebo (N = 63)	Combined dupilumab (N = 128)	Placebo (N = 40)	Dupilumab 300 mg q2w (N = 46)	Placebo (N = 67)	Dupilumab 300 mg q2w (N = 57)
BL FeNO, ppb, mean (SD)	42.27 (38.56)	40.18 (37.62)	34.03 (27.89)	35.91 (26.29)	39.64 (27.56)	27.71 (18.95)	39.61 (37.76)	41.86 (32.89)
Baseline, median (95% CI)	32.00 (26.00, 37.00)	27.50 (23.00, 33.00)	24.50 (20.00, 30.00)	30.00 (25.00, 35.00)	30.00 (24.00, 44.00)	23.00 (16.00, 30.00)	23.50 (18.00, 41.00)	36.50 (25.00, 44.00)
Q1-Q3	16.0-49.0	16.0-53.0	16.0-42.0	16.0-47.0	21.0-55.0	13.0-39.0	14.5-57.5	17.5-54.5
Change from baseline in FeNO at week 2, ppb								
	n = 79	n = 140	n = 54	n = 108	n = 32	n = 42	n = 58	n = 48
Median change from BL	-2.00	-8.00	0.00	-11.00	-4.00	-5.50	-2.00	-10.50
(95% CI)	(-6.00, 1.00)	(-13.00, -5.00)	(-3.00, 3.00)	(-15.00, -7.00)	(-7.00, 1.00)	(-10.00, -3.00)	(-5.00, -1.00)	(-16.00, -5.00)
Q1-Q3	-14.0 to 5.0	-29.0 to -1.0	-9.0 to 8.0	-25.0 to -1.0	-9.5 to 2.5	-23.0 to 0.0	-7.0 to 2.0	-31.0 to -3.5
P value vs placebo		< .0001		< .0001		.0032		.0004
Change from baseline in FeNO at week 24, pbb								
	n = 75	n = 137	n = 45	n = 101	n = 34	n = 41	n = 55	n = 47

Median change from BL	-2.00	-10.00	2.00	-10.00	0.00	-10.00	2.00	-13.00
(95% CI)	(-8.00, 1.00)	(-13.00, -6.00)	(-5.00, 6.00)	(-16.00, -6.00)	(-7.00, 4.00)	(-15.00, -3.00)	(-2.00, 6.00)	(-25.00, -8.00)
Q1-Q3	-18.0 to 5.0	-26.0 to -2.0	-10.0 to 10.0	-29.0 to 0.0	-10.0 to 7.0	-21.0 to 0.0	-10.0 to 10.0	-35.0 to -3.00
<i>P</i> value vs placebo		< .0001		< .0001		.0002		< .0001

77 *BL*, baseline; *CI*, confidence interval; *FeNO*, fractional exhaled nitric oxide; *Q*, quartile; *q2w*, every two weeks; *SD*, standard deviation.

78 **TABLE E8.** Change from baseline in serum TARC at weeks 4 and 24 in patients meeting and not meeting criteria for allergic asthma (exposed
 79 population)

	Phase 2B (24 weeks)				Phase 3 VENTURE (24 weeks)			
	Allergic phenotype		Did not meet criteria for allergic phenotype		Allergic phenotype		Did not meet criteria for allergic phenotype	
	Placebo	Combined	Placebo	Combined	Placebo	Dupilumab	Placebo	Dupilumab
	(N = 95)	dupilumab (N = 176)	(N = 63)	dupilumab (N = 128)	(N = 40)	300 mg q2w (N = 46)	(N = 67)	300 mg q2w (N = 57)
BL Serum TARC, pg/mL, mean (SD)	726.70 (1782.84)	493.96 (305.67)	414.64 (285.06)	607.74 (1158.21)	492.77 (884.42)	371.80 (365.48)	388.80 (486.58)	368.19 (233.51)
Baseline, median (95% CI)	377.28 (343.64, 439.89)	423.31 (383.28, 474.30)	330.58 (287.06, 457.90)	404.25 (373.88, 459.66)	291.00 (216.00, 356.00)	234.50 (173.00, 345.00)	281.50 (233.00, 313.00)	275.00 (257.00, 331.00)
Q1-Q3	267.87-577.82	305.64-641.77	228.79-502.92	285.60-596.63	161.00-550.00	134.00-475.00	170.00-402.00	232.00-448.00
Change from baseline in TARC at Week 4, pg/mL								
	n = 95	n = 173	n = 62	n = 128	n = 38	n = 44	n = 65	n = 54
Median change from BL (95% CI)	-15.41 (-45.61, 13.64)	-129.31 (-149.60, -108.39)	-11.50 (-73.37, 8.39)	-144.18 (-171.94, -103.93)	-2.50 (-17.00, 42.00)	-60.50 (-100.20, -26.00)	-2.00 (-35.00, 28.00)	-115.50 (-151.00, -90.00)
Q1-Q3	-126.05 to 51.89	-225.43 to -61.24	-120.19 to 49.46	-227.73 to -48.77	-61.00 to 97.00	-180.60 to -13.90	-56.00 to 62.00	-216.00 to -61.00
P value vs placebo		< .0001		.0003		0.0010		< .0001

Change from baseline in TARC at week 24, pg/mL

	n = 90	n = 166	n = 55	n = 119	n = 40	n = 45	n = 63	n = 56
Median change from BL	-17.65	-129.21	9.54	-139.78	-2.50	-62.00	17.00	-107.50
(95% CI)	(-32.70, 11.84)	(-154.42, -91.76)	(0.84, 31.96)	(-160.35, -109.58)	(-63.00, 36.00)	(-104.80, -29.50)	(-10.00, 56.10)	(-155.00, -58.00)
Q1-Q3	-120.23 to 80.43	-224.96 to -48.78	-49.53 to 115.69	-226.33 to -49.69	-97.50 to 50.45	-137.00 to -20.50	-65.00 to 91.00	-193.75 to -25.50
P value vs placebo		< .0001		< .0001		.0007		< .0001

80

BL, baseline; CI, confidence interval; Q, quartile; q2w, every two weeks; SD, standard deviation; TARC, thymus and activation-regulated chemokine.

FIGURE E1. Percent Change from baseline in specific IgE (95%CI) against (A) *Dermatophagoides farinae*, (B) *Dermatophagoides pteronyssinus*, (C) *Alternaria tenuis/alternata*, (D) cat dander, (E) dog dander, (F) German cockroach, (G) oriental cockroach, (H) *Cladosporium herbarum/hormodendrum*, (I) *Aspergillus fumigatus* in exposed patients with baseline serum specific-IgE levels ≥ 0.35 kU/mL for each allergen and meeting criteria for allergic asthma.

Journal Pre-proof